|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: April 2024
Volume 9 | Issue 4
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 95
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | Dostralimab in Rectal Cancer: A Comprehensive Review |
| Authors Name: | Akhila Bollam , Harshini Kancherla , Priyanka Patlolla , Vyshnavi Bodla , Ramya Bala Prabha G |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_182338
|
| Published Paper Id: | IJNRD2208026 |
| Published In: | Volume 7 Issue 8, August-2022 |
| DOI: | |
| Abstract: | Cancer is a large group of diseases that can start in almost any organ or tissue of the body. Rectal wall is made up of layers of tissue. Cancer begins in the innermost layer that comes in touch with food. Dostarlimab is a humanized monoclonal antibody that is developed for the treatment of various cancers. Brand name of Dostarlimab is jemperli. Dosage of Dostarlimab in adults include Dose 1 through 4 of jemperli is 500mg every 3weeks. Common side effects of Dostarlimab may include abnormal liver function tests, nausea, diarrhoea, constipation, low white blood cell counts, anaemia, or feeling weak or tired. Dostarlimab belong to class of drugs called anti-programmed cell death-1 (PD-1) monoclonal antibodies, immune checkpoint inhibitors, programmed death-ligand 1 (PD-L1) blocking antibodies. This drug was initially tried in treating uterine cancer and it was found to be effective. The recent study by the memorial Sloan Kettering cancer centre, New York, is the first clinical investigation that shown its effectiveness against rectal cancer. In the trial patients had stage II or III cancer and drug was given every three weeks for six months. The trial shown dramatic results that there are no apparent signs of tumour after at least follow-up for six months in rectal cancer patients. Locally advanced rectal cancer is usually managed by neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum. Recent evidence suggests that use of neoadjuvant therapy in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin followed by chemotherapy and then surgery.In recent clinical trial Dostarlimab is used for rectal cancer and it shown prominent result. But longer follow-up is needed to assess the drug drug whether disease cautious to be uncontrolled or whether the drug is safe. |
| Keywords: | Rectal Cancer, Dostarlimab, Jemperli, Chemotherapy, Immune checkpoint inhibitors. |
| Cite Article: | "Dostralimab in Rectal Cancer: A Comprehensive Review", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.7, Issue 8, page no.233-238, August-2022, Available :http://www.ijnrd.org/papers/IJNRD2208026.pdf |
| Downloads: | 000118758 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2208026 Registration ID: 182338 Published In: Volume 7 Issue 8, August-2022 DOI (Digital Object Identifier): Page No: 233-238 Country: Hyderabad, Telangana, India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2208026 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2208026 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn